Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: BioMérieux, Integrated Diagnostics, BioAffinity Technologies, And More

NEW YORK (360Dx) – BioMérieux this week released consolidated financial statements for the year ended Dec. 31, 2017, confirming the earnings it reported in January. For the full-year 2017, the firm reported that total revenues rose 9 percent to €2.29 billion ($2.82 billion) from €2.10 billion in 2016. The company also reported that the net income of its consolidated companies rose to €238 million, or €2.02 per share, in 2017, from €179 million, or €1.52 per share, in 2016.

Integrated Diagnostics Holdings’ lab in Cairo has received accreditation from the College of American Pathologists. The lab was built in 2015 and received CAP accreditation under the college’s laboratory accreditation program. IDH was created in 2012 following the merger of Al Mokhtabar and Al Borg Laboratories and provides more than 1,000 diagnostic services, including pathology and molecular diagnostics, genetics testing, and basic radiology across four central labs in the Middle East.

BioAffinity Technologies said it has been approved for membership in the Early Detection Research Network (EDRN), an initiative of the National Cancer Institute (NCI).  EDRN brings government, academic, and industry leaders together to accelerate the discovery, development, and validation of biomarkers for cancer risk and early detection. "Collaboration with the National Cancer Institute’s Early Detection Research Network is an important step in the development of CyPath Lung, our noninvasive, early-stage lung cancer test," Maria Zannes, president and CEO of BioAffinity Technologies, said in a statement. “EDRN and its members share many of our objectives, including expanding our knowledge of the biology of cancer, developing and testing promising technologies for the early detection of cancer, and promoting collaboration to advance the clinical application of tests like CyPath Lung.”

Clinical genomics interpretation software provider Congenica announced this week that it has received ISO 13485:2016 certification, a quality management system for medical devices that supports comprehensive policies and processes across the entire business. ISO 13485 is a global standard for medical devices and IVD production.

Fluidigm said this week that it has entered into separate privately negotiated transactions to exchange about $125 million in aggregate principal amount of its 2.75 percent convertible senior notes due in 2034 for about $125 million in aggregate principal amount of new 2.75 percent exchange convertible senior notes due in 2034. Each $1,000 principal amount of existing notes will be exchanged for $1,000 principal amount of exchange notes.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the 360Dx site.